Defendant
9 cases as defendant.
Antitrust action by United HealthCare Services against Jazz in D. Minn. It cites the '106 patent among patents at issue and was terminated April 15, 2021.
Antitrust action in which drugpatentwatch lists the '219 patent.
Antitrust case citing the '275 patent as part of an alleged Orange Book/patent-thicket scheme; terminated Apr. 15, 2021 in D. Minn.
Antitrust action terminated April 15, 2021, likely transferred to the Xyrem MDL.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; settled and voluntarily dismissed with prejudice July 16, 2025.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 14, 2020.
Antitrust/class action in which the '400 patent is cited as part of the alleged Xyrem patent/settlement thicket, not asserted. Transferred into the N.D. Cal. Xyrem antitrust MDL; terminated at N.D. Ill. July 15, 2020.
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
MDL antitrust litigation in which the '650 patent is identified in complaints as one of the Xyrem patents central to the alleged evergreening/sham-litigation scheme. Final settlement approval order entered Oct. 27, 2025.